Bristol-Myers Squibb, AstraZeneca commence SAVOR-TIMI 53 trial of ONGLYZA for type 2 diabetes
Bristol-Myers Squibb Company and AstraZeneca today announced the commencement of the “Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus” trial, a multicenter, randomized, double-blind, placebo-controlled Phase 4 study, to evaluate treatment with ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 inhibitor, in adult type 2 diabetes patients with cardiovascular …
Read more on News-Medical-Net
Incoming search terms
Related posts:
- New Herbal Supplement Helps Reduce Diabetes Risks, Offers $1 One Month Trial
- How to Cure Type 2 Diabetes Naturally?
- ~~What natural supplements can I take to for type 2 diabetes?
- Study Shows Vitamin D can prevent and fix type 1 diabetes
- Q&A: If you are pregnant and have Diabetes Type 1, will you be more likely to have to have a C-Section?